Dihydropyrimidine dehydrogenase expression predicts survival outcome and chemosensitivity to 5-fluorouracil in patients with oral squamous cell carcinoma

Oral Oncology

Volumn 41, Issue 1, 2005, Pages 38-47

  Kobayashi, Hiroichi ^a   Koike, Takeshi ^a   Nakatsuka, Atsushi ^a   Kurita, Hiroshi ^a   Sagara, Junji ^b   Taniguchi, Shun'ichiro ^b   Kurashina, Kenji ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY   (Japan)

Author keywords

Chemosensitivity; DPD; Immunohistochemistry; Oral squamous cell carcinoma; Prognosis

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; NEDAPLATIN; TEGAFUR;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; GENETIC HETEROGENEITY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; STAINING; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 10644249758     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2004.06.003     Document Type: Article

References (30)

1. D.M. Parkin, P. Pisani, and J. Ferlay Estimate of the worldwide incidence of 25 major cancers in 1999 Int. J. Cancer 83 1999 18 29
2. E.E. Vokes, R.R. Weichselbaum, S.M. Lippman, and W.K. Hong Head and neck cancer N. Engl. J. Med. 328 1993 184 194
3. N. Tanaka, T. Odajima, K. Ogi, T. Ikeda, and M. Satoh Expression of E-cadherin, alpha-catenin, and beta-catenin in the process of lymph node metastasis in oral squamous cell carcinoma Br. J. Cancer 89 2003 557 563
4. H.H. Vora, N.G. Shah, D.D. Patel, T.I. Trivedi, and P.R. Chikhlikar Prognostic significance of biomarkers in squamous cell carcinoma of the tongue: mutivariate analysis J. Surg. Oncol. 82 2003 34 50
5. S. Itoh, K. Matsui, I. Furuta, and Y. Takano Immunohistochemical study on overexpression of cyclooxygenase-2 in squamous cell carcinoma of the oral cavity: its importance as a prognostic predictor Oral. Oncol. 39 2003 829 835
6. M.C. Etienne, S. Cheradame, J.L. Fischel, P. Formento, O. Dassonville, and N. Renee Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity J. Clin. Oncol. 13 1995 1663 1670
7. K. Anan, S. Mitsuyama, K. Tamae, N. Suehara, K. Nishihara, and Y. Ogawa Increased dihydropyrimidine dehydrogenase activity in breast cancer J. Surg. Oncol. 82 2003 174 179
8. M. Terashima, T. Irinoda, H. Fujiwara, T. Nakaya, A. Takagane, and K. Abe Role of thymidylate synthase and dihydropyrimidine dehydrogenase on tumor progression and sensitivity to 5-fluorouracil in human gastric cancer Anticancer Res. 22 2002 761 768
9. K. Yoshinare, T. Kubota, M. Watanabe, N. Wada, H. Nishibori, and H. Hasegawa Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens Cancer Sci. 94 2003 633 638
10. E. Yamamoto, G. Kohama, H. Sunagawa, M. Imai, and H. Hiratsuka Mode of invasion, bleomycin sensitivity, and clinical course in squamous cell carcinoma of the oral cavity Cancer 51 1983 2175 2180
11. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 210
12. Y. Shimosato, S. Oboshi, and K. Baba Histological evaluation of effect of radiotherapy and chemotherapy for carcinomas Jpn. J. Clin. Oncol. 1 1971 19 35
13. G. Kawasaki, I. Yoshitomi, S. Yamamoto, and A. Mizuno Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 94 2002 17 23
14. K. Oka, T. Nakano, and T. Hoshi Transient increases of growth fraction during fractionated radiation therapy for cervical carcinoma. Ki-67 and PC10 immunostaining Cancer 72 1993 2621 2627
15. K.Y. Lam, I.O. Ng, A.P. Yuen, D.L. Kwong, and W. Wei Cyclin D1 expression in oral squamous cell carcinoma: clinicopathological relevance and correlation with p53 expression J. Oral Pathol. Med. 29 2000 167 172
16. Y. Tokunaga, M. Nakagami, A. Tokuka, and K. Ohsumi Prognostic effects of dihydropyrimidine dehydrogenase in advanced colorectal cancer after surgery: immunohistochemistry using a new monoclonal antibody Anticancer Res. 23 2003 1763 1768
17. J. Horiguchi, H. Takei, Y. Koibuchi, K. Iijima, J. Ninomiya, and K. Uchida Prognositic significance of dihydropyrimidine dehydrogenase expression in breast cancer Br. J. Cancer 86 2002 222 225
18. Y. Mizutani, H. Wada, M. Fukushima, O. Yoshida, O. Ukimura, and A. Kawauchi The significance of dihydropyrimidine dehydrogase (DPD) activity in bladder cancer Eur. J. Cancer 37 2001 569 575
19. R. Fujiwaki, K. Hata, K. Nakayama, M. Fukumoto, and K. Miyazaki Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influence outcome in epithelial ovarian cancer J. Clin. Oncol. 18 2000 3946 3951
20. M. Terashima, H. Fujiwara, A. Takagane, K. Abe, T. Irinoda, and T. Nakaya Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer Gastric Cancer 6 2003 71 81
21. R.M. Nagler, H. Kerner, D. Laufer, S. Ben-Eliezer, I. Minkov, and O. Ben-Itzhak Squamous cell carcinoma of the tongue: the prevalence and prognostic role of p53, Bcl-2, c-erB-2 and apoptotic rate as related to clinical and pathological characteristics in a retrospective study Cancer Lett. 186 2002 137 150
22. K. Sakurai, M. Urade, Y. Takahashi, H. Kishimoto, K. Noguchi, and H. Yasoshima Increased expression of c-erB-3 protein and proliferating cell nuclear antigen during development of verrucous carcinoma of the oral mucosa Cancer 89 2000 2597 2605
23. A. Beck, M.C. Etienne, S. Cheradame, J.L. Fischel, P. Formento, and N. Renee A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil Eur. J. Cancer 30A 1994 1517 1522
24. H. Nozawa, H. Tsukui, K. Nishida, K. Yakumaru, H. Nagawa, and T. Sekikawa Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma Cancer Chemother. Phamacol. 49 2002 263 273
25. Y. Hirano, T. Takayama, S. Kageyama, T. Ushiyama, K. Suzuki, and K. Fujita Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil Eur. Urol. 43 2003 43 52
26. M. Morifuji, S. Taniguchi, H. Sakai, Y. Nakabeppu, and M. Ohishi Differential expression of cytokeratin after orthotopic implantation of newly established human tongue cancer cell lines of defined matastatic ability Am. J. Pathol. 156 2000 1317 1326
27. B.E. Miller, F.R. Miller, D. Wilburn, and G.H. Heppner Dominance of tumor subpopulation line in mixed heterogeneous mouse mammary tumors Cancer Res. 48 1988 5747 5753
28. J.T. Leith, S. Michelson, L.E. Faulkner, and S.F. Bliven Growth properties of artificial heterogeneous human colon tumors Cancer Res. 47 1987 1045 1051
29. B.E. Miller, L.H. Matherly, M. Lehotan, and G.H. Heppner Rates of development of methotrexate resistance in heterogeneous mouse mammary tumor cell cultures J. Exp. Ther. Oncol. 1 1996 30 38
30. B.E. Millar, T. Machemer, M. Lehotan, and G.H. Heppner Tumor subpopulation interactions affecting melphalan sensitivity in palpable mouse mammary tumors Cancer Res. 51 1991 4378 4387